Whereas over 2,900,000 families in the United States live with prostate cancer; Whereas 1 in 7 men in the United States will be diagnosed with prostate cancer in their lifetimes; Whereas prostate cancer is the most commonly diagnosed nonskin cancer and the third-leading cause of cancer-related deaths among men in the United States; Whereas the American Cancer Society estimates that in 2017, 161,360 men will be diagnosed with, and more than 26,730 men will die of, prostate cancer; Whereas 43 percent of newly diagnosed prostate cancer cases occur in men under the age of 65; Whereas the odds of developing prostate cancer rise rapidly after age 50; Whereas African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have double the prostate cancer mortality rate than that of White men; Whereas having a father or brother with prostate cancer more than doubles the risk of a man developing prostate cancer, with a higher risk for men who have a brother with the disease and the highest risk for men with several affected relatives; Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent; Whereas only 29 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized; Whereas there are no noticeable symptoms of prostate cancer in the early stages, making appropriate screening critical; Whereas, in fiscal year 2017, the Director of the National Institutes of Health supported approximately $274,000,000 in research projects focused specifically on prostate cancer; Whereas ongoing research promises further improvements in prostate cancer prevention, early detection, and treatment